Clinical Trial Update: Study of Vorinostat (MK-0683) With Follicular Lymphoma (FL), Other Indolent B-cell Non-Hodgkin's Lymphoma (B-NHL), or Mantle Cell Lymphoma (MCL) Participants (MK-0683-103) [Phase 2]

View source ↗

Summary

Phase 2 study MK-0683-103 evaluated vorinostat in follicular lymphoma, other indolent B-cell non-Hodgkin lymphomas, and mantle cell lymphoma. Results were poste…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma
• Indolent Non-hodgkin Lymphoma
• Mantle Cell Lymphoma

Drugs mentioned

• Vorinostat (vorinostat)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2020-10-29